Document Detail


Urinary albumin excretion and the renin-angiotensin system in cardiovascular risk management.
MedLine Citation:
PMID:  17150005     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Microalbuminuria has been shown to be a strong predictor of cardiovascular morbidity and mortality in diabetic and hypertensive patients, but also in the general population. Moreover, several reports suggest that reduction of urinary albumin excretion (UAE) is associated with improvement of cardiovascular prognosis. Reduction of UAE can be achieved by lowering arterial blood pressure, but blockers of the renin-angiotensin system (RAS) with their specific renal actions have demonstrated to be able to reduce UAE more than might be expected from reduction of blood pressure alone. Consequently, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may also provide superior cardiovascular protection, especially in subjects with higher levels of albuminuria, but evidence is still scarce. The ability of both angiotensin-converting enzyme inhibitors and angiotensin receptor blockers to reduce UAE and provide cardiovascular protection suggests that the RAS may play a central role. New developments in this area include the use of aldosterone antagonists in albuminuric/proteinuric subjects, and the development of oral renin inhibitors. Combinations of the aforementioned drugs may have the ability to fully block the RAS, potentially avoiding all detrimental effects of this hormonal cascade. However, combination therapy is expected to also increase the incidence of side effects, such as hyperkalaemia and acute renal insufficiency. The current knowledge of microalbuminuria represents the proverbial tip of the iceberg, and future studies should focus on the underlying pathophysiological mechanism of urinary albumin excretion in relation to cardiovascular protection. Only then can a better understanding of the problem be achieved and the optimal pharmacological approach be ascertained.
Authors:
R M A Van de Wal; A A Voors; R T Gansevoort
Related Documents :
185095 - Renin--angiotensin antagonists and the regulation of blood pressure.
9825185 - Neurohumoral response to carmoxirole, a selective dopamine (d2) receptor agonist, in pa...
6986225 - Response of chronic renovascular hypertension to surgical correction or prolonged block...
1116245 - Continuous inhibition of renin release in dogs by vagally innervated receptors in the c...
15019285 - Association between the interleukin-1beta c(-511)t polymorphism and blood pressure in a...
6895845 - Increased effective vascular compliance and venous pooling of intravascular volume duri...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  7     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2006 Dec 
Date Detail:
Created Date:  2006-12-07     Completed Date:  2007-01-08     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  2505-20     Citation Subset:  IM    
Affiliation:
St Antonius Hospital, Department of Cardiology, Nieuwegein, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Albuminuria / drug therapy,  urine*
Cardiovascular Diseases / physiopathology*,  prevention & control,  urine*
Disease Management
Humans
Renin-Angiotensin System / drug effects,  physiology*
Risk Factors
Serum Albumin / metabolism*
Chemical
Reg. No./Substance:
0/Serum Albumin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Insulin infusion therapy for myocardial infarction.
Next Document:  Fixed combination isosorbide dinitrate-hydralazine for nitric-oxide-enhancing therapy in heart failu...